Pulmatrix Stock Today
| PULM Stock | USD 2.54 0.03 1.17% |
PerformanceWeakest
| Odds Of DistressRisky
|
Pulmatrix is selling at 2.54 as of the 5th of February 2026; that is 1.17 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.54. Pulmatrix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 7th of November 2025 and ending today, the 5th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of March 2014 | Category Healthcare | Classification Health Care |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. The company has 3.65 M outstanding shares of which 7.04 K shares are at this time shorted by private and institutional investors with about 0.2 trading days to cover. More on Pulmatrix
Moving against Pulmatrix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pulmatrix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Teofilo MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPulmatrix utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Pulmatrix's leverage profile, showing how much of Pulmatrix's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pulmatrix (PULM) is traded on NASDAQ Exchange in USA and employs 2 people. Pulmatrix is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.5 M. Pulmatrix conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 3.65 M outstanding shares of which 7.04 K shares are at this time shorted by private and institutional investors with about 0.2 trading days to cover.
Pulmatrix currently holds about 42.91 M in cash with (10.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pulmatrix Probability Of Bankruptcy
Ownership AllocationRoughly 89.94 pct. of Pulmatrix outstanding shares are held by general public with 0.66 % owned by insiders and only 9.4 (%) by third-party entities.
Check Pulmatrix Ownership Details
Pulmatrix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2025-06-30 | 110.8 K | |
| Jones Financial Companies Lllp | 2025-06-30 | 0.0 | |
| Sbi Securities Co Ltd | 2025-06-30 | 60.6 K | |
| Blackrock Inc | 2025-06-30 | 55.3 K | |
| Vanguard Group Inc | 2025-06-30 | 47 K | |
| Geode Capital Management, Llc | 2025-06-30 | 41.1 K | |
| State Street Corp | 2025-06-30 | 13.9 K | |
| Ubs Group Ag | 2025-06-30 | 5.5 K | |
| Tower Research Capital Llc | 2025-06-30 | 408 | |
| Citigroup Inc | 2025-06-30 | 90.0 | |
| Bank Of America Corp | 2025-06-30 | 36.0 |
Pulmatrix Historical Income Statement
Pulmatrix Stock Against Markets
Pulmatrix Corporate Management
| MBA CMA | Interim Officer | Profile | |
| Alexander Klibanov | Founder | Profile | |
| Margaret MD | Chief Officer | Profile | |
| David JD | Advisor | Profile | |
| Aidan Curran | VP Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.